Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Peritoneal Metastases

NCT06003998 is registered in ClinicalTrials.gov with Catharina Ziekenhuis Eindhoven as lead sponsor.

NCT NCT06003998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Peritoneal Metastases
Lead sponsor
Catharina Ziekenhuis Eindhoven
Phase
Phase 2
Overall status
Unknown status
Start date
December 27, 2022
Completion date
January 1, 2025
Enrollment
85 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, peritoneal metastases